High-Dose Quadrivalent Influenza Vaccine for Prevention of Cardiovascular and Respiratory Hospitalizations in Older Adults

CONCLUSIONS: Despite insufficient statistical power due to the impact of COVID-19, rVE point estimates demonstrated a trend toward a benefit of QIV-HD over QIV-SD. QIV-HD was associated with lower respiratory or cardiovascular hospitalization rates than QIV-SD, with a comparable safety profile. Adequately powered studies conducted over multiple influenza seasons are needed to determine statistical significance of QIV-HD compared with QIV-SD against preventing respiratory and cardiovascular hospitalizations.TRIAL REGISTRATION: ClinicalTrials.gov number: NCT04137887.PMID:38569647 | PMC:PMC10990679 | DOI:10.1111/irv.13270

Source: Respiratory Care - April 3, 2024 Category: Respiratory Medicine Authors: Arto A Palmu Stephanie Pepin Ritva K Syrj änen Karine Mari Tamala Mallett Moore Jukka Jokinen Heta Nieminen Terhi Kilpi Sandrine I Samson Iris De Bruijn Source Type: research